Denali Therapeutics Inc.
HealthcareNASDAQ:DNLI · NASDAQ Global Select
+$0.64 today
Vol 2.17M · Avg 1.80M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-50.6%
avg -14.2%
ROIC
-52.6%
avg -28.7%
ROA
-44.8%
avg -24.0%
Analysis
ROA is currently the strongest return metric at -44.8% versus its period average of -24.0%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Ryan J. Watts | Co-Founder, President, Chief Executive Officer & Director | $1.42M | — | 50 | $296,833.00 | 0.19% |
Alexander O. Schuth | Co-Founder, Chief Financial Officer, Chief Operating Officer & Secretary | $926,175.00 | — | 53 | $282,828.00 | 0.18% |
Katie Peng | Chief Commercial Officer | — | — | 55 | — | — |
Joe Lewcock | Chief Scientific Officer | — | — | — | — | — |
Cindy Dunkle | Chief People Officer | — | — | — | — | — |
Chris Walsh | General Counsel | — | — | — | — | — |
Dana Andersen | Chief Technical and Manufacturing Officer | — | — | — | — | — |
Peter Chin | Acting Chief Medical Officer & Head of Development | — | — | 58 | $33,941.00 | 0.02% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
2
$22,857.14
Sells
6
$8.39M
Net Sentiment
$8.36M
Net selling
Most Active
Watts Ryan J.
2 transactions
Analysis
Insiders reported 2 buys worth $22,857.14 and 6 sells worth $8.39M over the last 12 months. That adds up to net selling of $8.36M. Watts Ryan J. was the most active insider with 2 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A5 analysts |
| Revenue | N/A | N/A | N/A | +37.0% (11yr)7 analysts |
| Net Income | N/A | N/A | N/A | N/A7 analysts |
| EBIT | N/A | N/A | N/A | N/A7 analysts |
Analysis
Forward estimates point to Revenue at +37.0% (11yr), giving you a quick read on expected growth from here.
Competitors
Peer companies in the same sector
ImmunityBio, Inc.
NASDAQ:IBRX
$7.44B
Liquidia Corporation
NASDAQ:LQDA
$6.33B
Cogent Biosciences, Inc.
NASDAQ:COGT
$5.66B
Beam Therapeutics Inc.
NASDAQ:BEAM
$2.99B
Arcus Biosciences, Inc.
NYSE:RCUS
$2.40B
89bio, Inc.
ETNB
$2.20B
Galapagos N.V.
GLPG
$1.84B
Agios Pharmaceuticals, Inc.
NASDAQ:AGIO
$1.75B
Viridian Therapeutics, Inc.
NASDAQ:VRDN
$1.47B
Recursion Pharmaceuticals, Inc.
NASDAQ:RXRX
$1.41B
Who manages DNLI?
Denali Therapeutics Inc. (DNLI) lists 8 active executives. The top listed executive is Katie Peng, Chief Commercial Officer.
Are DNLI insiders buying or selling?
Recent insider activity shows net buying of $16.51M.
Explore More
Continue the stock analysis
Jump to another research area for this company.